ArticleBioinformation2025
Analytical study on systemic lupus erythematosus and its association with cutaneous manifestations.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune illness with cutaneous involvement being the most frequent of its clinical presentations. Therefore, it is of interest to determine the prevalence and patterns of cutaneous manifestations among SLE patients and their relationship with disease activity. Data comparison of 120 SLE patients was done based on demographic profile, nature of the cutaneous lesions and association with disease activity indices like the SLE disease activity index (SLEDAI). It was found that 75% of the patients presented with cutaneous involvement, of which malar rash was the most frequent manifestation, followed by discoid lesions and photosensitivity. Higher SLEDAI scores were significantly associated with more severe cutaneous symptoms (p < 0.01). The findings underscore the importance of early recognition and treatment of skin lesions for optimal disease outcome in SLE patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.